Defense World
19 Jul 2026, 08:01 UTC · 9w ago
Verdict
Headline takes no side. We score ACHV +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Raymond James Financial initiated coverage of Achieve Life Sciences with a "strong-buy" rating and a $20.00 price objective.
So whatA strong-buy rating combined with a price target significantly above current trading levels ($6.35) serves as a bullish catalyst for investors.
More positive than 92% of claims this week
Achieve Life Sciences reported quarterly earnings per share of ($0.19), beating the analyst consensus estimate of ($0.30).
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 77% of claims this week
The consensus analyst rating for the company is "Buy" with an average target price of $16.00.
So whatBroad analyst agreement on a valuation significantly higher than the current price suggests strong fundamental conviction.
More positive than 63% of claims this week
Bank of America Corp DE increased its position in Achieve Life Sciences by 39.9% during the second quarter.
More positive than 50% of claims this week
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+24.4%
Price agrees with the score
$7.80 vs $6.27 close before publication (Jul 17) · not market-adjusted
ACHV chart →
